Inflammation

Healio | OSN Chief Medical Editor Richard L. Lindstrom, MD, a leader in corneal, cataract, refractive and laser surgery, has been appointed as founder and chairman of Surface Ophthalmics, according to a press release.

A law allowing for medical cannabis research could have far-reaching implications in rheumatology and across the health care spectrum, but there are still significant hurdles to clear before cannabinoids become part of routine care.

The FDA has granted priority review to dupilumab to treat adults with uncontrolled COPD with type 2 inflammation, according to a manufacturer-issued press release.

MIAMI BEACH, Fla. — Zabalafin, a nonsteroidal topical, demonstrated efficacy in reducing inflammation and bacteria on the skin of children and adults with atopic dermatitis, according to interim data presented in a poster at Masters of Pediatric Dermatology.

TAMPA, Fla. — In this Healio Video Perspective from Telling It Like It Is, Steven M. Silverstein, MD, FACS, discusses safety data for Dextenza for the treatment of perioperative ocular pain and inflammation and allergic conjunctivitis.

Heart disease continues to be the leading cause of death and disability in the U.S. and worldwide. Atherosclerotic CVD, which is caused by plaque buildup in arterial walls, contributes to multiple life-threatening conditions.

MIAMI BEACH, Fla. — Xerosis can be a significant issue for patients as they age and dermatology practioners should both be aware and remain vigilant with whole body checks in older patients according to a poster presentation here.

Jonathan A. Bernstein, MD, president of the American Academy of Allergy, Asthma & Immunology, is very excited about the group’s Annual Meeting, scheduled for Feb. 23-26 in Washington, D.C.

MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.

Silo Pharma will advance a portfolio of four drugs in its 2024 clinical pipeline, targeting conditions related to mental health, chronic pain and neurology.